ABBV Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
AbbVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$148.25 |
| 52 Week High | US$168.11 |
| 52 Week Low | US$130.96 |
| Beta | 0.55 |
| 1 Month Change | 0.034% |
| 3 Month Change | 9.81% |
| 1 Year Change | 7.18% |
| 3 Year Change | 68.60% |
| 5 Year Change | 56.37% |
| Change since IPO | 323.57% |
Recent News & Updates
AbbVie Inc.'s (NYSE:ABBV) Intrinsic Value Is Potentially 59% Above Its Share Price
Sep 25
AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths
Sep 15Recent updates
AbbVie Inc.'s (NYSE:ABBV) Intrinsic Value Is Potentially 59% Above Its Share Price
Sep 25AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths
Sep 15AbbVie (NYSE:ABBV) Seems To Use Debt Quite Sensibly
Sep 07AbbVie: Balance Is Everything
Sep 04AbbVie: Still A Buy According To Buffett's 10xEBT Rule
Aug 23Abbott Labs Vs AbbVie: Which One Is The Best Investment Choice?
Aug 03Unveiling AbbVie's Hidden Risks: Cautionary Notes For Investors
Jul 28AbbVie: Loss Of Exclusivity Is A Natural End Process
Jul 21More Challenges Await AbbVie Following A Disappointing Quarter
Jul 14AbbVie: Use This Buying Opportunity (Rating Upgrade)
Jul 06Is There An Opportunity With AbbVie Inc.'s (NYSE:ABBV) 44% Undervaluation?
Jun 21AbbVie: A Pharmaceutical Powerhouse Despite Humira Challenges
Jun 16AbbVie Stock May Be Falling On Humira LOE - But Investors Shouldn't Panic
Jun 05Is AbbVie (NYSE:ABBV) Using Too Much Debt?
May 22An Intrinsic Calculation For AbbVie Inc. (NYSE:ABBV) Suggests It's 43% Undervalued
Mar 17AbbVie, Capsida expand team up to develop genetic therapies for eye diseases
Feb 23Does AbbVie (NYSE:ABBV) Have A Healthy Balance Sheet?
Feb 15Is AbbVie Stock A Buy After Earnings? Consider Revenue Outlook And Valuations
Feb 13AbbVie: The Dreaded Humira Cliff Is Here: Time To Sell?
Feb 05AbbVie: Why The Company Is Still Overvalued
Jan 29BioMed X, AbbVie extend partnership to focus on immunology research
Jan 17AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.48
Jan 072023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit
Jan 01AbbVie's (NYSE:ABBV) Upcoming Dividend Will Be Larger Than Last Year's
Dec 21If EPS Growth Is Important To You, AbbVie (NYSE:ABBV) Presents An Opportunity
Dec 20AbbVie: Clouds Keep Thickening Due To Lack Of Revolutionary Drugs
Dec 13AbbVie: I Won't Sell Till P/E Reaches 14x
Dec 07AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.48
Dec 02AbbVie to pay $54.4M to resolve lawsuit linked to Alzheimer's drug Namenda
Nov 16AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.48
Nov 16AbbVie candidate for postoperative atrial fibrillation fails in mid-stage trial
Nov 07AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.48
Oct 31Shareholder Returns
| ABBV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.1% | -1.4% | -1.1% |
| 1Y | 7.2% | 6.2% | 14.1% |
Return vs Industry: ABBV exceeded the US Biotechs industry which returned 6.2% over the past year.
Return vs Market: ABBV underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| ABBV volatility | |
|---|---|
| ABBV Average Weekly Movement | 2.6% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in US Market | 14.1% |
| 10% least volatile stocks in US Market | 2.6% |
Stable Share Price: ABBV is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: ABBV's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 50,000 | Rick Gonzalez | https://www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine.
AbbVie Inc. Fundamentals Summary
| ABBV fundamental statistics | |
|---|---|
| Market Cap | US$263.10b |
| Earnings (TTM) | US$8.64b |
| Revenue (TTM) | US$56.02b |
30.3x
P/E Ratio4.7x
P/S RatioIs ABBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABBV income statement (TTM) | |
|---|---|
| Revenue | US$56.02b |
| Cost of Revenue | US$16.54b |
| Gross Profit | US$39.48b |
| Other Expenses | US$30.85b |
| Earnings | US$8.64b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.89 |
| Gross Margin | 70.47% |
| Net Profit Margin | 15.41% |
| Debt/Equity Ratio | 476.0% |
How did ABBV perform over the long term?
See historical performance and comparisonDividends
4.0%
Current Dividend Yield120%
Payout RatioDoes ABBV pay a reliable dividends?
See ABBV dividend history and benchmarks| AbbVie dividend dates | |
|---|---|
| Ex Dividend Date | Oct 12 2023 |
| Dividend Pay Date | Nov 15 2023 |
| Days until Ex dividend | 9 days |
| Days until Dividend pay date | 43 days |
Does ABBV pay a reliable dividends?
See ABBV dividend history and benchmarks